文献速递类风湿关节炎

体重指数升高与类风湿关节炎患者对传统合成改善病情抗风湿药治疗反应的相关性:METEOR数据库结果

The association between increased body mass index and response to conventional synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: results from the METEOR database.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

基于国际类风湿关节炎数据库1313例患者(44.3%为早期RA),探讨超重或肥胖对csDMARDs处方、甲氨蝶呤剂量及12个月疾病活动度的影响。早期RA中BMI升高与缓解无显著相关;已确诊RA中肥胖单药治疗者6个月EULAR良好反应和DAS28缓解率显著更低,且更可能接受csDMARDs联合治疗。服用MTX的超重和肥胖患者(早期和已确诊RA,单药及联合)暴露于更高MTX剂量,平均20 mg/周,而正常BMI者为15 mg/周。

要点

  • 已确诊RA中肥胖单药治疗者6个月EULAR良好反应和DAS28缓解率显著低于正常BMI者。
  • 超重和肥胖的早期及已确诊RA患者接受MTX治疗时平均剂量为20 mg/周,正常BMI者为15 mg/周。
  • 早期RA中BMI升高与缓解无显著相关,但已确诊RA中BMI升高与反应降低相关。

核心结论

  • 与正常BMI患者相比,超重和肥胖个体接受更密集的csDMARDs暴露。
  • 早期RA中BMI升高与缓解无显著相关,但已确诊RA中BMI升高与反应降低相关。

研究设计与样本

  • 国际类风湿关节炎数据库参与者被分为早期RA(诊断后<1年)和已确诊RA。
  • 在基线、6个月和12个月记录EULAR反应、DAS28缓解和治疗,使用逻辑回归和线性回归分析。

主要发现

  • 共分析1313例患者数据,44.3%为早期RA。
  • 已确诊RA中肥胖单药治疗者6个月时达到EULAR良好反应或DAS28缓解的可能性显著更低,且更可能接受csDMARDs联合治疗。
  • 服用MTX的超重和肥胖患者(早期和已确诊RA,单药及联合)平均MTX剂量为20 mg/周,正常BMI者为15 mg/周。

关键数值与推荐

  • 早期RA中BMI升高与缓解无显著相关。
  • 已确诊RA中肥胖单药治疗者6个月时EULAR良好反应和DAS28缓解率显著更低。
  • 超重和肥胖患者MTX平均剂量20 mg/周,正常BMI者15 mg/周。

临床怎么用

  • 对已确诊RA合并肥胖的患者,应关注csDMARDs反应可能减弱,并考虑优化靶向治疗。
  • 超重和肥胖RA患者接受MTX治疗时可能使用更高剂量(平均20 mg/周)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few data exist on the association between increased BMI and response to conventional synthetic DMARDs (csDMARDs) in RA. We aimed to explore the association between increased (overweight or obese) BMI on csDMARD prescribing, MTX dose and disease activity over 12 months. METHODS: Participants in an international RA database were stratified into early (<1 year post-diagnosis) and established RA. EULAR response, 28-joint DAS (DAS28) remission and treatments were recorded at baseline, 6 months and 12 months. Increased BMI was explored in early and established RA as predictors of good EULAR response, DAS28 remission, number of csDMARDs and MTX dose, using logistic and linear regression. RESULTS: Data from 1313 patients, 44.3% with early RA, were examined. In early RA, increased BMI was not significantly associated with remission. In established RA, obese patients on monotherapy were significantly less likely to achieve good EULAR response or DAS28 remission at 6 months and more likely to be treated with combination csDMARDs compared with normal BMI. In patients taking MTX, overweight and obese patients with early and established RA were exposed to higher MTX doses (mono- and combination therapy), with a mean dose of 20 mg/week, compared with 15 mg/week in those of normal BMI. CONCLUSION: We observed that compared with patients with normal BMI, overweight and obese individuals experienced more intensive csDMARD exposures. Similar response rates were observed in early RA but increased BMI was associated with reduced response in established RA. Optimization of targeted RA treatment remains important, particularly in those with increased BMI where response in established disease may be attenuated.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Dey M, Zhao SS, Moots RJ, et al. The association between increased body mass index and response to conventional synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: results from the METEOR database. Rheumatology (Oxford). 2022. PMID: 33930113. doi:10.1093/rheumatology/keab389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。